Implementation and outcomes of monoclonal antibody infusion for COVID-19 in an inner-city safety net hospital: A South-Bronx experience도심 안전망 병원에서 COVID-19에 대한 단일 클론 항체 주입의 구현 및 결과: South-Bronx 경험Observational Study Published on 2022-01-012022-09-12 Journal: Journal of the National Medical Association [Category] 임상, 진단, [키워드] approval bamlanivimab bamlanivimab-etesevimab casirivimab-imdevimab conducted control group Coronavirus disease 2019 COVID-19 criteria declined Disease progression drug Emergency use authorization EUA Factor FDA food group high risk Hispanic Hospitalization Logistic majority MAT a Mild Mild-moderate COVID-19 moderate Moderate COVID-19 monoclonal antibody monoclonal antibody therapy Mortality mortality. offered outcome p value Patient patient population protocol reduced reported retrospective risk severe disease South statistically significant reduction symptomatic improvement the study group the United State therapy Treatment treatment group [DOI] 10.1016/j.jnma.2021.08.036 PMC 바로가기 [Article Type] Observational Study
SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED PatientsSARS-CoV-2 스파이크 단백질 유도 단클론 항체는 APECED 환자의 COVID-19 합병증을 개선할 수 있습니다Clinical Trial Published on 2021-08-242022-09-11 Journal: Frontiers in Immunology [Category] MERS, SARS, 변종, 임상, 진단, 치료법, [키워드] administration Admission AIRE antibody APECED APS-1 autoantibody Autoimmune autoimmune regulator bamlanivimab bamlanivimab-etesevimab candidiasis caused center clinical Clinical effect Complication Course COVID-19 COVID-19 infection COVID-19 pneumonia COVID-19 symptom COVID-19 symptoms death develop drug early treatment Efficacy Emergency use authorization enrolled entry of SARS-CoV-2 etesevimab evaluated food high risk high-risk patient High-risk patients Hospitalization host cells IFNs immune Infection intensive care interferons interferons (IFNs invasive life-threatening loss-of-function mutation loss-of-function mutations mAb mAbs Mild-to-moderate monoclonal antibodies monoclonal antibody Neutralizing NIH nucleocapsid protein Patient patients Pneumonia Pneumonitis prophylactically protocol reduced SARS-CoV-2 SARS-CoV-2 spike protein severe disease spike Spike protein syndrome the SARS-CoV-2 type-1 IFN autoantibodies US Food and Drug Administration ventilatory support without affecting [DOI] 10.3389/fimmu.2021.720205 PMC 바로가기 [Article Type] Clinical Trial